Skip to main content
OpenTrials
Completed

NCT Number: NCT03692182

The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Behavioral and Psychiatric Symptoms of Dementia Behavior Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders

Age range

55 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tabula Rasa HealthCare

Moorestown, New Jersey, 08057, United States

About this study

Much national attention has been given to assessing and reducing the use of antipsychotics among nursing home residents, yet comparatively little attention has focused on antipsychotic use among older adults receiving care in community-based settings. The primary objective of this study is to determine the prevalence of antipsychotic use among a nationally representative sample of nursing home-eligible older adults in a community-based practice setting known as Program of All-inclusive Care for the Elderly (PACE). The secondary objectives are focused on characterizing antipsychotic use within PACE and for these participants. Specifically, the investigator's secondary objectives are to describe patterns of other drugs concomitantly used with antipsychotics (e.g., benzodiazepines, opioids) and to identify clinically relevant drug-drug interactions involving antipsychotics.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant enrolled in PACE contractually receiving pharmacy services from Tabula Rasa Healthcare CareKinesis Pharmacy (Tabula Rasa HealthCare) during the project time period (January 2017 through December 2017).

Exclusion criteria

  • Participant with a diagnosis of bipolar disorder and/or schizophrenia, according to pharmacy records.

Treatment and study plan

Primary outcomes

  1. Prevalence of Antipsychotic Use

    Time frame: 12 months

    Quantitative description of antipsychotic use as assessed by pharmacy records

Secondary outcomes

  1. Concomitant Drug Use with Antipsychotics

    Time frame: 12 months

    Qualitative and quantitative description of patterns of other drugs concomitantly used with antipsychotics as assessed by pharmacy records

  2. Drug-Drug Interactions

    Time frame: 12 months

    Qualitative and quantitative description of drug-drug interactions involving antipsychotics as assessed by proprietary clinical decision support system (CDSS)

Sponsors and collaborators

Lead sponsor

Tabula Rasa HealthCare

Industry

Registry information

Official study title

Antipsychotic Use Within the Program of All-inclusive Care for the Elderly (PACE)

Important dates

Study start
2017
Primary completion
2017
Study completion
2019
First posted
Oct 2, 2018
Registry last updated
Sep 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.